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Abstract 
Background: Massive pulmonary embolism (PE) is associated with significant mortality, especially if compounded 
by haemodynamic instability, right ventricular (RV) dysfunction and right atrial (RA) thrombus. Thrombolysis can be 
lifesaving in patients with major embolism and cardiogenic shock, and accelerates the resolution of thrombus. Only 
three fibrinolytic agents—namely streptokinase, urokinase, and recombinant tissue plasminogen activator (alteplase) 
have been approved in the treatment of PE, with studies demonstrating similar safety profiles.
Case presentation: We report the case of a 33-year-old Bangladeshi Bengali female with a history of recent ankle 
fracture and immobilization, who presented with massive PE, leading to cardiac arrest. Upon rapid resuscitation, 
urgent echocardiogram revealed RV dysfunction with floating RA thrombus, and she was successfully treated with 1.5 
million IU of streptokinase over 2 h as per accelerated regimen recommended by the European Society of Cardiology 
guidelines, resulting in successful resolution of the right heart thrombus, and significant clinical improvement. Subse-
quent CT pulmonary angiogram confirmed the diagnosis of PE, and she was anticoagulated to a PT/INR of 2.0–3.0 for 
3 months.
Conclusions: Echocardiography is a suitable alternative for rapid diagnosis of acute massive PE associated with RA 
thrombus and cardiovascular collapse, especially when a delay to CT pulmonary angiogram may be anticipated, and 
in the setting of immediate cardio-pulmonary resuscitation. Thrombolysis is a rapid and life-saving therapeutic meas-
ure in such cases.
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Background
Massive pulmonary embolism (PE) is frequently compli-
cated with hypotension and shock, leading to mortality 
rates exceeding 50 % [1, 2]. Patients with right ventricular 
(RV) dysfunction are another subgroup with a guarded 
prognosis [3], as are those with right heart thrombus [4–
6]. These patients in particular, benefit from more inten-
sive therapy with thrombolytic agents in comparison to 
anticoagulant therapy alone, resulting in reduced mortal-
ity to less than 30 % [2, 6]. Thrombolytic therapy accel-
erates the resolution of PE, while reducing its recurrence 
and improving other parameters, such as pulmonary 
blood flow, lung perfusion, and RV dysfunction [4, 7]. 
Streptokinase, urokinase and recombinant tissue plasmi-
nogen activator (alteplase) are the thrombolytic agents 
approved for the treatment of PE, with alteplase being 
explicitly identified as the agent indicated for acute mas-
sive PE [7]. This case report aims to demonstrate the 
importance of prompt imaging and intervention, and the 
superior efficacy of thrombolysis in complicated massive 
PE.
Case presentation
A 33-year-old normotensive, non-diabetic Bangladeshi 
Bengali female presented with sudden onset severe ret-
rosternal chest pain and two episodes of syncope over 
4  h. Chest pain was worse on deep inspiration and 
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associated with shortness of breath, orthopnoea and pal-
pitations for 2  days. She had an ankle fracture and was 
on a cast with plaster immobilization for the preceding 
month, and admitted to unilateral leg pain and swelling.
On admission, she was cyanosed with gasping respi-
ration; pulse and blood pressure were non-recordable. 
She developed asystole soon after, and reverted to sinus 
rhythm following 2  min of cardio pulmonary resuscita-
tion (CPR). After resuscitation, heart rate was 136 beats/
min and blood pressure was 80/55  mmHg. SpO2 was 
90 %. Respiratory rate was 35 breaths/min. She was given 
high flow oxygen, intravenous (IV) normal saline and 
dopamine infusion for hypotension. Electrocardiogram 
(ECG) revealed sinus tachycardia (rate 136/min), right 
bundle branch block (RBBB) with S1Q3T3 pattern (Fig. 1). 
Bedside echocardiogram revealed dilated right atrium 
(RA) and RV (Fig.  2), floating thrombus in RA (Fig.  3; 
Additional file 1: Video S1); impaired RV systolic function 
[tricuspid annular planar systolic excursion (TAPSE) was 
9  mm] with no evidence of RV hypertrophy; there was 
mild tricuspid regurgitation and pulmonary hypertension 
with pulmonary artery systolic pressure ~45 mmHg and 
normal left ventricular systolic function (ejection frac-
tion 60  %). Immediate thrombolysis was done with IV 
streptokinase 1.5 million units over 2 h as per accelerated 
regimen of European Society of Cardiology (ESC) guide-
lines, resulting in a subsequently normal ECG (Fig.  4). 
Subsequent CT pulmonary angiogram done immedi-
ately revealed an approximately 2 cm filling defect in the 
descending branch of left pulmonary artery extending 
up to the lateral and posterior basal segmental arteries, 
suggesting thrombus (Fig.  5). d-dimer assay was posi-
tive. Troponin-I was 1.27 ng/mL (high risk—0.11–0.60). 
Complete blood count revealed neutrophilic leucocyto-
sis. As she had no episodes of bleeding following throm-
bolysis, she was commenced on low molecular weight 
heparin (LMWH) at a dose of 1  mg/kg body weight 
for 5  days with simultaneous oral warfarin titrated to a 
therapeutic PT/INR of 2.0–3.0. Review echo done 2 days 
later revealed no thrombus or pulmonary hypertension, 
normal RA and RV. She was discharged on warfarin 5 mg 
daily and was asymptomatic with therapeutic PT/INR 
at 3 month follow up. She denied use of the oral contra-
ceptive pill and was advised against its use owing to its 
potential as a risk factor. Hypercoagulability evaluation 
including Protein C and S levels, antinuclear antibody, 
anticardiolipin antibody and serum homocysteine levels 
were within normal range, thus eliminating other causes 
of hypercoagulability as possible aetiology of thrombosis.
Discussion
This case of acute PE presented with cardiorespira-
tory arrest and is classified as massive PE as per Ameri-
can Heart Association (AHA) definitions [7]. The AHA 
defines massive PE as acute PE with sustained hypo-
tension (systolic blood pressure <90  mmHg for at least 
15 min or requiring inotropic support, not due to a cause 
other than PE), pulselessness, or persistent profound 
bradycardia (heart rate <40  bpm with signs or symp-
toms of shock) [7]. ESC guidelines also classify suspected 
acute PE as ‘high risk’ on the basis of presence of shock or 
hypotension [4].
Emergency multidetector CT should be performed in 
haemodynamically unstable suspected PE patients with 
shock or hypotension, because of its 97 % sensitivity for 
detecting emboli in the main pulmonary arteries [6, 7]. 
Fig. 1 Electrocardiogram showing sinus tachycardia, right bundle branch block, “S-1Q-3T-3 pattern”
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If unavailable, echocardiography should be performed 
without delay [4, 6, 7]. Echocardiographic markers of RV 
dysfunction, such as RV dilatation (without hypertrophy), 
paradoxical septal systolic motion, and pulmonary hyper-
tension are independent predictive factors of poor out-
come in acute PE [8]. Echocardiography can also detect 
right heart thrombi, a marker of worse prognosis, the 
prevalence of which is 4–18 % in the setting of an acute PE 
[9], and usually found in those more haemodynamically 
compromised [5, 6]. Free-floating right heart thrombi, are 
almost exclusively associated with PE [10, 11].
Elevated d-dimers and positive cardiac troponin T or I, 
both of which have a high negative predictive value, can 
be used for immediate risk stratification [4, 7, 12]. A nor-
mal d-dimer level renders acute PE or deep vein throm-
bosis (DVT) unlikely.
Scoring systems may be adopted for early risk stratifi-
cation of patients, taking into account the clinical status 
and risk factors for venous thromboembolism (VTE) 
such as lower limb fractures, major trauma and sur-
gery [7]. With a Well’s Score of 9, and a Revised Geneva 
Score of 11, our patient had high clinical probability of 
PE [13, 14]. According to 2014 ESC guidelines, she had 
high early mortality risk owing to shock, RV dysfunc-
tion on imaging and positive cardiac laboratory mark-
ers, thus warranting primary reperfusion [4]. There is 
no contraindication to fibrinolysis in cases of cardiac 
arrest owing to PE, however thrombolysis is discour-
aged in those with undifferentiated cardiac arrest [7]. 
Where patient transport for CT is unsafe, thrombolysis 
should be considered in case of unequivocal signs of RV 
overload on bedside echocardiography, and CT per-
formed later [6].
There are three thrombolytics approved for the treat-
ment of PE by the Food and Drug Administration (FDA): 
streptokinase, urokinase and alteplase, with alteplase 
being explicitly identified as the agent indicated for mas-
sive PE in 2010 [7]. There are no conclusive findings from 
studies comparing different thrombolytic regimens in 
acute PE, with most of them demonstrating similar safety 
profiles [15–17]. However, short infusion times (2  h or 
less) are recommended over prolonged infusion times, as 
they achieve more rapid thrombolysis and probably less 
bleeding [7, 18].
Thrombolytic treatment of acute PE restores pulmo-
nary function more rapidly than anticoagulation with 
unfractionated heparin (UFH) alone [4]. Thrombolytic 
agents actively promote the hydrolysis of fibrin mol-
ecules, resulting in rapid resolution of thromboembolic 
obstruction. At 24  h, patients treated with adjunctive 
fibrinolysis manifest a 30–35 % reduction in total perfu-
sion defect [7, 18]. This leads to a prompt reduction in 
pulmonary artery pressure and resistance, with a con-
comitant improvement in RV function, stabilization of 
respiratory and cardiovascular function, and prevention 
of PE recurrence [7]. Major contraindications include 
haemorrhagic or ischaemic stroke, recent major surgery 
or trauma or known bleeding risk [4, 17].
Thrombolysis has mortality benefit when compared 
either to anticoagulation or surgical thromboembolec-
tomy, in cases of right heart thrombus [19]. A study by 
Rose et  al. [19] revealed that the mortality rate associ-
ated with no therapy, anticoagulation therapy, surgical 
embolectomy, and thrombolysis was 100.0, 28.6, 23.8 
and 11.3  %, respectively in patients with right heart 
thrombo-emboli. Thus, in PE in the presence of right 
Fig. 2 Trans-thoracic echocardiogram showing dilated right heart. 
Two-dimensional echocardiography in apical four chamber view 
showing dilated right atrium and right ventricle
Fig. 3 Trans-thoracic echocardiogram showing thrombus. Two-
dimensional echocardiography in apical five chamber view showing 
thrombus (white arrow) in the dilated right atrium
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heart thrombi, thrombolysis demonstrated an improved 
survival rate (p  <  0.05) when compared with either to 
anticoagulation therapy or surgery.
Emergency surgical embolectomy or catheter 
embolectomy with fragmentation has been recom-
mended for patients with massive PE or submassive PE 
with RV dysfunction, and contraindications to fibrinoly-
sis or failed thrombolysis, provided appropriate exper-
tise and resources are available [7, 20, 21]. Transfer to 
a centre in which these facilities are available should 
be considered for those patients with contraindication 
to thrombolysis or failed thrombolysis. The decision to 
proceed with either catheter-based or surgical embolec-
tomy requires inter-disciplinary teamwork and operator 
expertise [7, 20]. Catheter-based embolectomy is gen-
erally reserved for cases in which neither thrombolysis 
nor surgical embolectomy is possible [1, 7], or in cases 
where thrombolysis has failed to improve haemodynam-
ics in the acute setting. Operator expertise is essential 
[7]. Hybrid therapy that includes both catheter-based 
clot fragmentation and local thrombolysis is an emerg-
ing strategy [7].
Furthermore, in patients with acute PE, anticoagulation 
is recommended, with the objective of preventing both 
early death and recurrent symptomatic or fatal VTE [4]. 
This acute-phase parenteral anticoagulation may com-
prise of subcutaneous LMWH, IV or subcutaneous UFH 
or subcutaneous fondaparinux over the first 5–10  days, 
overlapping with oral vitamin K antagonist, warfarin [4, 
7]. As our patient had already been thrombolysed and 
had no subsequent bleeding manifestations, she was 
commenced on LMWH.
Fig. 4 Electrocardiogram after thrombolysis, showing normal sinus rhythm, rate 72 beats/min
Fig. 5 a CT pulmonary angiography showing thrombus. b CT 
pulmonary angiogram shows filling defects in descending branch of 
left pulmonary artery (arrow heads in b) extending up to segmental 
arteries, suggesting thrombus
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LMWHs have many advantages over UFH. They have 
a greater bioavailability, can be administered by subcu-
taneous injections, and have a longer duration of antico-
agulant effect. A fixed dose of LMWH can be used, and 
laboratory monitoring of activated partial thromboplas-
tin time (aPTT) is not necessary [22].
Clinical trials comparing LMWH with UFH have 
shown that LMWH is comparable or superior to, and as 
safe as UFH [22]. Moreover, LMWH or fondaparinux are 
preferred over UFH for initial anticoagulation in PE, as 
they carry a lower risk of inducing major bleeding and 
heparin-induced thrombocytopenia [4]. Alternatively, 
UFH is recommended for patients in whom primary rep-
erfusion is considered, as well as for those with serious 
renal impairment (creatinine clearance <30 mL/min), or 
severe obesity. Our patient received streptokinase imme-
diately after resuscitation, following confirmation of RA 
thrombus by echocardiography, and suggestive ECG of 
acute PE. As such, this recommendation was not appli-
cable in this situation, and LMWH was commenced 
and continued until therapeutic INR was achieved. As 
patients with acute PE are at risk for recurrent throm-
boembolism, they should be given long-term antico-
agulation. The recommendation for PE secondary to a 
reversible risk factor is therapy with vitamin K antago-
nists for 3 months, titrated to a target INR of 2.0–3.0 [4, 
6]. Novel oral anticoagulants (NOACs) i.e. dabigatran, 
rivaroxaban and apixaban are as effective and safe as war-
farin for the treatment of VTE [4, 6, 7].
Follow up of patients is important, due to implica-
tions of long term anticoagulation and the possibility of 
chronic thromboembolic pulmonary hypertension after 
an acute PE, the incidence of which is up to 3.8 % 2 years 
after the acute event [23].
Conclusions
Acute massive PE associated with RA thrombus, RV dys-
function and cardiovascular collapse is a cardiac emer-
gency requiring prompt diagnosis and treatment, which 
can be life-saving. Echocardiography is a suitable alterna-
tive for rapid diagnosis of such cases, especially when a 
delay to CT pulmonary angiogram may be anticipated, 
and in the setting of immediate CPR. The effects of 
thrombolysis are extremely rewarding in cases of PE with 
cardiovascular collapse.
Additional file
Additional file 1: Video S1. Trans-thoracic echocardiogram in apical four 
chamber view showing floating thrombus in right atrium.
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